A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment IM Administered Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)

NCT00492765 Phase 4 COMPLETED

This study is to find out if there is any benefit to adding Simvastatin to Interferon-beta-1a in patients with Multiple Sclerosis.

Details

Lead sponsor	Biogen
Phase	Phase 4
Status	COMPLETED
Enrolment	380
Start date	2006-02
Completion	2010-04

Conditions

• Multiple Sclerosis

Interventions

• Interferon-beta-1a
• Simvastatin
• Placebo

Primary outcomes

• The time to first documented relapse — months 4, 6, 9, 12, and every 3 months from months 18-39

Countries

Denmark